

- Users.” *International Journal of Drug Policy*, vol. 33, pp. 23:37–44, 2012.
8. Bicket, M., Long, J., Pronovost, P., et al., “Prescription Opioid Analgesics Commonly Used After Surgery: A Systematic Review.” *JAMA Surgery*, vol. 152, pp. 1066–1071, 2017 (available at doi:10.1001/jamasurg.2017.0831, published online August 2, 2017).
  9. Howard, R., Fry, B., Gunaseelan, V., et al., “Association of Opioid Prescribing with Opioid Consumption After Surgery in Michigan.” *JAMA Surgery*, vol. 154, p. e184234, 2019 (available at doi:10.001/jamasurg.2018.4234, published online November 7, 2018).
  10. Thiels, C., Ubl, D., Yost, K., et al., “Results of a Prospective, Multicenter Initiative Aimed at Developing Opioid-Prescribing Guidelines After Surgery.” *Annals of Surgery*, vol. 268, pp. 457–468, 2018 (available at doi:10.1097/SLA.0000000000002919).
  11. Mundkur, M., Meyer, T., Menzin, T., et al., “Estimating the Optimal Duration of Initial Opioid Analgesic Prescriptions in Post-Surgical Populations Using FDA’s Sentinel Distributed Database.” *Pharmacoepidemiology and Drug Safety*, S2: Abstracts of the 34th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Abstract #392, vol. 27, p. 181 (available at doi:10.1002/pds.4629).
  12. Steiner, C.A., Karaca, Z., Moore, B.J., et al., “Surgeries in Hospital-Based Ambulatory Surgery and Hospital Inpatient Settings, 2014.” *HCUP Statistical Brief #223*, 2017 (available at [www.hcup-us.ahrq.gov/reports/statbriefs/sb223-Ambulatory-Inpatient-Surgeries-2014.pdf](http://www.hcup-us.ahrq.gov/reports/statbriefs/sb223-Ambulatory-Inpatient-Surgeries-2014.pdf)).
  13. Mundkur, M., unpublished data.
  - \* 14. Mundkur, M., Franklin, J., Abdia, Y., et al., “Days’ Supply of Initial Opioid Analgesic Prescriptions and Additional Fills for Acute Pain Conditions Treated in the Primary Care Setting—United States, 2014.” *Morbidity and Mortality Weekly Report*, vol. 68, pp. 140–143, 2019.
  - \* 15. Dowel, D., Haegerich, T., and Chou, R., “CDC Guideline for Prescribing Opioids for Chronic Pain—United States, 2016.” *Morbidity and Mortality Recommended Weekly Report*, vol. 65(1), pp. 1–49, 2016.
  16. Opiate Prescribing Engagement Network, “Emergency Department Prescribing Recommendations” (available at <http://michigan-open.org/emergency-department-prescribing-recommendations/>), accessed January 5, 2019.
  17. Ohio Opiate Action Team, “Ohio Guidelines for Emergency and Acute Care Facility Opioid and Other Controlled Substances (OOCs) Prescribing” (available at <https://mha.ohio.gov/Portals/0/assets/Initiatives/GCOAT/Guidelines-ED-Acute-Care.pdf>), accessed January 5, 2019.
  18. New York City Emergency Department, “Discharge Opioid Prescribing Guidelines” (available at <https://www1.nyc.gov/assets/doh/downloads/pdf/basas/opioid-prescribing-guidelines.pdf>), accessed January 5, 2019.
  19. Thiels, C., Ubl, D., Yost, K., et al., “Results of a Prospective, Multicenter Initiative Aimed at Developing Opioid-Prescribing Guidelines After Surgery.” *Annals of Surgery*, vol. 268, pp. 457–468, 2018.
  20. The Regents of the University of Michigan, “Opioid Prescribing Recommendations for Surgery” (available at <https://opioidprescribing.info/>), last updated April 11, 2019, accessed April 17, 2019.
  21. Overton, H., Hanna, M., Bruhn, W., et al., “Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus.” *Journal of the American College of Surgeons*, vol. 227, pp. 411–418, 2018.
- Dated: May 24, 2019.
- Lowell J. Schiller**,  
Principal Associate Commissioner for Policy.  
[FR Doc. 2019–11283 Filed 5–30–19; 8:45 am]

BILLING CODE 4164–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Center for Scientific Review; Amended Notice of Meeting

Notice is hereby given of a change in the meeting of the Lung Cellular, Molecular, and Immunobiology Study Section, June 4, 2019, 08:00 a.m. to June 5, 2019, 03:00 p.m., Hilton Baltimore Inner Harbor, 401 W Pratt Street, Baltimore, MD 21201, which was published in the **Federal Register** on April 16, 2019, 84 FR PG 15624.

The meeting location is being changed to Hilton Baltimore Inner Harbor, 401 W Pratt Street, Baltimore, MD 21201. Meeting dates remain the same. The meeting is closed to the public.

Dated: May 24, 2019.

**Natasha M. Copeland**,  
Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2019–11328 Filed 5–30–19; 8:45 am]

BILLING CODE 4140–01–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Mental Health; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meeting will be closed to the public in accordance with the

provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; NIMH Pilot Effectiveness Trials for Treatment, Preventive, and Services Interventions (R34).

*Date:* June 18, 2019.

*Time:* 11:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

*Contact Person:* Marcy Ellen Burstein, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6143, MSC 9606, Bethesda, MD 20892, 301–443–9699, [bursteinme@mail.nih.gov](mailto:bursteinme@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; NCDDG & First in Human and Early Stage Clinical Trials for Psychiatric Disorders.

*Date:* June 18, 2019.

*Time:* 3:30 p.m. to 5:30 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

*Contact Person:* Vinod Charles, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6151, MSC 9606, Bethesda, MD 20892, 301–443–1606, [charlesvi@mail.nih.gov](mailto:charlesvi@mail.nih.gov).

*Name of Committee:* National Institute of Mental Health Special Emphasis Panel; Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (R01).

*Date:* June 25, 2019.

*Time:* 12:00 p.m. to 3:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institutes of Health, Neuroscience Center Building (NSC), 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

*Contact Person:* Rebecca Steiner Garcia, Ph.D., Scientific Review Officer, Division of Extramural Activities, National Institute of Mental Health, NIH, Neuroscience Center, 6001 Executive Blvd., Room 6149, MSC 9608, Bethesda, MD 20892, 301–443–4525, [steinerr@mail.nih.gov](mailto:steinerr@mail.nih.gov).

(Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS)